Vireo Health Launches 1937 Cannabis Brand

Vireo Health Launches 1937 Cannabis Brand

Original Post: CFN Media Group: Vireo Health Launches 1937 Cannabis Brand

[Canniseur: Interesting name. 1937 was the year that cannabis was first banned in the U.S. The company advertises that they are featuring historic cannabis strains. Um, no they’re not. Bubba Kush and Sweet Cheese are not the landrace (original) strains that they are purported to be. The story goes on to state that they use a long curing process, etc. I’d sure like to see this cannabis. If companies continue this kind of undocumented hype, they’ll hurt many other companies trying to grow special products.]

1937 Cannabis features historic cannabis strains and will be available in both dry flower and concentrates

MINNEAPOLIS, Oct. 17, 2019 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), a leading physician-founded, science-focused multi-state cannabis company, today announced the launch of 1937 Cannabis, a new brand of professional grade cannabis-based products. 1937 Cannabis represents the Company’s first launch of a new cannabis brand and first time offering dry flower. The 1937 Cannabis product line features dry flower and will expand to include concentrates later this year.

1937 Cannabis ( is now available in dispensaries throughout Pennsylvania and Maryland and features legendary strains such as ‘Bubba Kush’ and ‘Sweet Cheese’ that are handpicked and hand-packaged to assure only the best flower is utilized. The flower is cured for extended time periods to create a smoother taste, enhanced terpene profile, and deeper aromatics. 1937 Cannabis is 100% pesticide free and sold in premium, airtight glass jars.

“We are excited to announce the launch of 1937, a new line of premium-quality cannabis products,” said CEO and Founder Kyle Kingsley, MD. “By expanding our product lines to include dry flower, we are increasing access and affordability, while providing our customers – both cannabis connoisseurs and medical patients alike – with new choices and opportunities to discover which products best meet their individual needs.”

“Vireo is developing a strong portfolio of brands that engage and delight both recreation and medical consumers,” added Harris Rabin Chief Marketing Officer of Vireo Health. “1937 is our second major brand, but we are creating and launching a variety of exciting, new brands for every occasion our customers have to enjoy cannabis products.”

The brand name, 1937, is a reference to The Marihuana Tax Act of 1937, federal legislation designed to prohibit cannabis use. As Americans across the country work to end cannabis prohibition, the 1937 brand proudly stands for social justice and equality for all.

The Company plans to expand the 1937 Cannabis product line in Pennsylvania and Maryland and to make it available in other state-based markets in which Vireo is licensed to operate.

Learn more at: or follow the brand on Instagram

About Vireo Health International, Inc.
Vireo Health International, Inc.’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry. Vireo’s physician-led team of nearly 400 employees provides best-in-class cannabis products and customer experience. Vireo cultivates cannabis in environmentally friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. The Company currently is licensed in eleven markets including Arizona, Maryland, Massachusetts, Minnesota, New Mexico, New York, Nevada, Ohio, Pennsylvania, Puerto Rico, and Rhode Island. For more information about the Company, please visit

Contact Information

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
(267) 221-4800

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
(612) 314-8995



The post Vireo Health Launches 1937 Cannabis Brand appeared first on CannabisFN.

Original Post: CFN Media Group: Vireo Health Launches 1937 Cannabis Brand

Israel Builds Dominant Position in the Global Medical Cannabis Industry

Israel Builds Dominant Position in the Global Medical Cannabis Industry

Original Post: CFN Media Group: Israel Builds Dominant Position in the Global Medical Cannabis Industry

[Canniseur: Why should anyone be surprised by this? Israel has been dominant in cannabis research for decades. Now Israel is building itself to be one of the leaders, if not the leader in cannabis research and supply for the medical industry. Although this is a sponsored article, it’s worthwhile to note what Israeli science is doing to promote what is emerging as the single most potent plant (other than food crops) that can benefit humans.]

Israel has always been a leader in cannabis research and development—thanks to Raphael Mechoulam’s groundbreaking research—but it’s just starting to realize the potential for cultivation. In addition to having one of the highest per capita usage rates in the world, Israel is expected to soon have upwards of 50,000 patients on a waitlist and is uniquely located to become a major supplier to Germany and other European end markets.

Isracann Biosciences Inc. [CSE: IPOT (Pending)] aims to become Israel’s first pure-play cannabis firm listed in Canada with a four-pronged focus on cultivation, distribution, products and manufacturing, and R&D genetics.

Click Here To Receive Isracann’s Investor Presentation

Why Israel Stands at the Forefront

Israel is a well-known global science and technology hub with more than four percent of its GDP devoted to civil research and development and 140 scientists and technicians per 10,000 employees. Most investors are familiar with Israeli companies like Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Ltd. (NASDAQ: WIX) that were born from this devotion to cutting-edge research and development.

Not surprisingly, Israel has also become a leader within the nascent cannabis industry. Raphael Mechoulam is widely recognized as the “Godfather of Cannabis” for discovering tetrahydrocannabinol (THC) and other cannabinoids. Earlier this year, the country doubled down on medical cannabis research by pouring $2.13 million into 13 cannabis research projects, making it one of just three countries with government funding for research.

Earlier this year, the Israeli Ministry of Agriculture officially classified the growing of medical cannabis as a ‘farming sector’, which paves the way for cannabis cultivators to receive government aid, grants, and water quotas like any other farmer. The Ministry of Health and Finance also recommended legalizing the export of medical cannabis, which experts believe could open the door to a $1 billion per year export market.

Building a Massive Footprint

Isracann is building 230,900 sq. ft. of hybrid greenhouses for the ultra-low-cost production of high-quality medical cannabis. Management expects these facilities to be completed by year end with an initial production capacity of 11,500 kilograms per year with the long-term goal of reaching 23,500 kilograms per year. The hybrid greenhouse has several advantages over indoor purpose-built greenhouses, including precise environmental controls and containment.

Through a distribution partnership in Malta, the company plans to efficiently export cannabis products to the European Union—and Germany in particular. The German market has 82.7 million citizens and serves as a key gateway to other European end markets, which could exceed North American end markets over time. New legislation passed earlier this year could pave the way for a new legal import framework.

While the company plans to deliver high-quality GMP flower for export in the early stages, management plans to expand into higher margin products, such as ultra-pure cannabinoid distillate that can be infused into a variety of products. At the same time, the company has partnered with leading research institutions and imports genetics from Canada and Holland to ensure that it’s offering the most competitive premium products.

Looking Ahead

Isracann Biosciences Inc.[CSE: IPOT (Pending)] is uniquely positioned to become a leader in Israel’s nascent cannabis industry. With a massive cultivation footprint and a four-pronged business plan, the company could begin generating revenue as early as next year. The country’s long-term potential to be a leader in R&D and a well-positioned exporter to Europe could make it the next big global cannabis destination.

Click Here To Receive Isracann’s Investor Presentation

For additional information, visit the company’s website at


The above article is sponsored content. Emerging Growth LLC, which owns and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation:

Original Post: CFN Media Group: Israel Builds Dominant Position in the Global Medical Cannabis Industry

These Bees Make Honey with Cannabis Resin

These Bees Make Honey with Cannabis Resin

Original Post: CFN Media Group: These Bees Make Honey with Cannabis Resin

[Canniseur: “Cannahoney”, not an infused product, could have therapeutic qualities. How do you train bees to harvest only cannabis pollen? If the bees are only gathering pollen from the males, which has almost no THC, how do they get THC containing resin into the honey? Is Mr. Trainerbees a bee whisperer?]

French beekeeper Nicolas Trainerbees (a nickname) is passionate about nature and has self-medicated with cannabis since a very early age. After training bees to collect sugar from fruits rather than flowers, he turned his attention toward the cannabis plant to merge his passions.

In 2006, he began training bees to collect the resin from cannabis plants and use them in the beehive to create what he has dubbed “cannahoney”. The honey contains terpenes and other cannabis features that add a “delicious and pleasant taste” reminiscent of the cannabis plant.

“For some time I had known about the health benefits of bee products such as honey, propolis, pollen, wax and royal jelly and also about the benefits of cannabis,” he says. For instance, the resin from willows, poplars and other trees is turned into propolis by bees, which has antiseptic, antibiotic, anti fungal and antibacterial properties.

He reasoned that bees using the resin from cannabis could similarly turn it into something that could be useful from a health standpoint — something different than the typical cannabis-infused honey that has already permeated many markets.

Since his original experiment, Nicolas’ project has grown to 30 beehives in a country that continues to enforce strict cannabis laws. His goal is to move out of France and into Spain to legally treat his illness and work with professionals in the space interested in his work.

As for the bees, they aren’t affected by cannabinoids because they do not have an endocannabinoid system like humans.

Original Post: CFN Media Group: These Bees Make Honey with Cannabis Resin

This City Looks to Become the ‘New Amsterdam’

This City Looks to Become the ‘New Amsterdam’

Original Post: CFN Media Group: This City Looks to Become the ‘New Amsterdam’

[Canniseur: In the long run, Vegas’s casinos should be nervous about ‘consumption’ cafes. In the short run, not so much. Until alcohol sales can be combined with toking, I don’t see the sustainability of consumption lounges. And, my prediction is…when it’s realized cannabis & a glass of whatever, is what people really want, that’s when lounges will win. Until then, people will pop into the lounge, toke up and then head to the casino.]

Las Vegas will become one of the few municipalities in the country to license cannabis consumption in lounges — a move that could transform the city into the ‘New Amsterdam’.

The Las Vegas City Council recently approved an ordinance that authorizes the so-called ‘social use venue’ licenses.

Under the new ordinance, existing licensed cannabis businesses may apply for a new $5,000 per year license to open a social use lounge. These establishments must be physically separated from cannabis retail locations, may not sell alcohol, and must be located at least 1,000 feet from schools and casinos. Entry is limited to patrons over the age of 21 and cannabis consumption is not permitted outside or in the public view.

Acres Cannabis, which operates a 19,000 sq. ft. store, plants to open a nearby consumption space featuring a concert hall and full-service kitchen. Councilman Bob Coffin, who sponsored the ordinance, believes that many cannabis businesses will open lounges adjacent to their retail locations.

Many casino operators are worried about the new industry, which isn’t permitted near casino properties. New cannabis lounges could draw the city’s millions of tourists away from casinos and hotels, where they traditionally spend most of their entertainment time and money. For now, the Nevada Gaming Control Board has warned that casinos friendly to cannabis users could lose their licenses.

Original Post: CFN Media Group: This City Looks to Become the ‘New Amsterdam’

Big Banks Snub Cannabis Banking Bill

Big Banks Snub Cannabis Banking Bill

Original Post: CFN Media Group: Big Banks Snub Cannabis Banking Bill

[Canniseur: Great news! This leaves cannabis banking to the smaller banks, giving them a leg up in the industry. Those first in definitely will have the competitive edge. Further, I’d love to see the day where Chase Bank turns down Constellation Brands business.]

The SAFE Banking Act is making its way through the legislative process, but many big banks still plan on avoiding cannabis clients, according to a Wall Street Journal report. In fact, no major bank publicly supports the bill’s passage and any content between Congress and the bill were initiated by Congress.

While the SAFE Banking Act is designed to protect banks with cannabis clients from prosecution, banking leaders say that government-mandated compliance obligations remain a sticking point. Cannabis transactions remain illegal under federal money laundering rules and banks aren’t willing to take the risk until the drug is fully legal in the United States.

Many large banks were recently fined for inadequate anti-money laundering controls, which makes them even less likely to take the risk. For instance, US Bancorp paid $613 million in fines and penalties in February 2018 after failing to report suspicious activities to regulators and ignoring red flags for years.

The good news is that many smaller banks may be willing to assume the risk and open the door to legitimate banking for cannabis companies. In particular, credit unions and local banks in states where cannabis has been legalized could see a tremendous new growth opportunity.

Banking access enables cannabis companies to not only safely store their revenue, but also potentially access credit card processing, small business loans, mortgages, and other financial products that mainstream businesses enjoy.

Original Post: CFN Media Group: Big Banks Snub Cannabis Banking Bill

Cannabis News Highlights
Get Free Weekly News

Subscribe and get the best cannabis news of the week delivered directly to you.

Thank you for subscribing.

Something went wrong.